Onconase is a 12 kDa protein homologous to pancreatic RNase A isolated from amphibian oocytes which shows cytostatic and cytotoxic activity in vitro, inhibits growth of tumors in mice and is in phase III clinical trials. The present study was aimed to reveal mechanisms by which onconase perturbs the cell cycle progression. Human histiocytic lymphoma U937 cells were treated with onconase and expression of cyclins D3 and E, as well as of the cyclin-dependent kinase inhibitors (CKIs) p16 , the events which may prevent phosphorylation of pRb during G 0/1 and result in cell arrest at the restriction point controlled by Cdk4/6 and D type cyclins.
Introduction
Onconase, initially named Protein P30, 1 is a basic protein of 12 000 MW isolated from oocytes or early embryos of Rana pipiens. 2, 3 This protein is homologous to members of the pancreatic RNase superfamily and, although considerably less active than RNase A, also possesses ribonucleolytic activity. 2, 4, 5 Onconase shows antiproliferative activity in vitro, suppressing proliferation of tumor cell lines of different lineage including hematological tumors. [5] [6] [7] [8] [9] [10] [11] It also inhibits growth of certain tumors in mice. 12 In its antitumor activity onconase shows a synergism with tamoxifen; the mechanism of this synergism appears to be unrelated to the estrogenic properties of the latter. 13 Onconase is currently in phase III clinical trials in patients with advanced pancreatic adenocarcinoma and malignant mesothelioma. 14 Mechanism of antitumor activity of onconase is still poorly understood. With relatively high affinity the drug binds to plasma membrane of the sensitive cells and is internalized. 8, 10 Inhibition of protein synthesis was observed in 9L glioma cells treated with onconase and this effect was associated with its ribonucleolytic activity. The alkylated form of this protein which retained only 2% of the original ribonucleolytic activity Correspondence: Z Darzynkiewicz, Brander Cancer Research Institute, New York Medical College, 100 Grasslands Road, Elmsford, NY, 10595, USA; Fax: 914 347 2804 Received 2 January 1998; accepted 17 April 1998 was essentially ineffective. 8 It has been postulated, therefore, that the cytostatic and cytotoxic effects result from internalization of onconase followed by degradation of intracellular RNA, in particular tRNA, by this enzyme. 8 The cytostatic effect of onconase, which manifested as an increase in proportion of cells in G 1 phase of the cell cycle, 1 has become evident after 48-72 h of cells exposure and was accompanied by apoptotic cell death. 15 Considering that onconase shows low toxicity in animal tests 12 and in clinical trials 14, 16 it is unclear why tumor cells are more sensitive to this drug compared to normal cells.
In light of the evidence that onconase suppresses cell proliferation, 1, 8, 13 the aim of the present study was to investigate the effect of this drug on the specific components of the machinery of the cell cycle progression, namely cyclins and inhibitors of cyclin-dependent kinases (CKIs) (for reviews, see . In addition to standard methodology of analysis of these proteins in bulk by immunoblotting, we detected them in individual cells immunocytochemically. Using multiparameter flow cytometry it was possible to correlate expression of cyclins D3 and E as well as CDK inhibitors (CKIs) p21 WAF1/CIP1 , p16 INK4A and p27 KIP1 with the cell cycle position, as described before in other cell systems (for reviews, see Refs 23-25). Furthermore, using a recently developed immunocytochemical assay 26 we have been able to monitor the status of phosphorylation of retinoblastoma susceptibility gene protein (pRb). The data suggest that the onconase induced arrest of human histiocytic lymphoma U937 cells in G 1 may be a consequence of a decreased expression of cyclin D3 combined with increased expression of p27 KIP1 , p16
INK4A
and p21 WAF1/CIP1 , the events which inhibit phosphorylation of pRb.
Materials and methods

Cells
Human histiocytic lymphoma U-937 cells were purchased from American Type Culture Collection (Rockville, MD, USA) and were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml of penicillin, 100 g/ml streptomycin and 2 mm glutamine (all from Life Technologies, Grand Island, NY, USA) as described before.
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The suspension cultures were passaged by re-seeding the cells at a density of 1 × 10 5 cells/ml. The cells were studied during their exponential and asynchronous growth, generally within 72 h of their re-seeding in medium with fresh serum, before reaching density of 8 × 10 5 cells/ml. The cultures were periodically tested for Mycoplasma infection by staining of cytocentrifuge preparations with the DNA fluorochrome 4,6-diamidino-2-phenylindole (DAPI; Molecular Probes, Eugene, OR, USA). Onconase, provided by Alfacell (Bloomfield, NJ, USA), was diluted in RPMI to the final concentrations as shown in the Results and figure legends.
Immunocytochemical detection of cyclins and CKIs
Following incubations in the absence or presence of onconase, the cells were washed with phosphate-buffered saline (PBS) and fixed in suspension in either in ice-cold 80% ethanol or absolute methanol for up to 24 h. After fixation, the cells were washed twice with PBS and then suspended in 1 ml of 0.25% Triton X-100 (Sigma, St Louis, MO, USA) in PBS on ice for 5 min. The cells were then centrifuged (300 g, 5 min), the cell pellet suspended 100 l PBS containing 0.5 g of the anti-cyclin (or anti-CKI) moAb and 1% bovine serum albumin (BSA; Sigma), and incubated for 2 h at room temperature. Anti-cyclin D3 (clone G107-565); anti-cyclin E (clone HE12); anti-p16 INK4A (clone G175-405); anti p2 WAF1/CIP1 (clone SX118) and anti-p27 KIP1 (clone G173-524) mAbs, all were obtained from PharMingen, San Diego, CA, USA. After incubation with the respective mAbs the cells were rinsed with PBS containing 1% BSA and incubated with the FITC-conjugated goat anti-mouse IgG antibody (Molecular Probes) diluted 1:30 in PBS containing 1% BSA for 30 min at room temperature in the dark. The cells were washed again, resuspended in 5 g/ml of propidium iodide (PI; Molecular Probes) and 0.1% RNase A (Sigma) in PBS, and incubated at room temperature for 20 min prior to measurement. Additional details of the detection of cyclins by flow cytometry are presented elsewhere.
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Immunocytochemical detection of pRb phosphorylation
The status of phosphorylation of pRb in individual cells was monitored using a combination of anti-pRb antibodies, one specifically detecting underphosphorylated pRb (anti-pRb P− mAb) and another which reacts with total pRb, regardless of its phosphorylation (anti-pRb T mAb). This approach is described by us in detail in a separate publication. 26 Briefly, following incubations in the presence or absence of onconase the cells were washed with PBS and fixed in suspension in 1% methanol-free formaldehyde in PBS for 15 min on ice. The cells were then washed with PBS and resuspended in ice-cold 80% ethanol for up to 24 h. After fixation the cells were rinsed twice with PBS and then resuspended in 1 ml of 0.25% Triton X-100 in PBS on ice for 5 min. The cells were then centrifuged (300 g, 5 min) the cell pellet resuspended in 100 l of PBS containing 1% BSA and 0.5 g/ml of the anti-pRb T mAb (PharMingen, clone G3-245) conjugated with Cy-Chrome and/or with 1 g/ml of anti-pRb P− mAb (PharMingen, clone G99-549) conjugated with FITC, and incubated for 2 h at room temperature. The cells were then rinsed with PBS containing 1% BSA and their pRb associated green (anti-pRb 
Cell fluorescence measurements
Cellular fluorescence was measured with the ELITE ESP flow cytometer/cell sorter (Coulter, Miami, FL, USA) using either argon ion laser (emission at 488 nm) alone or combined with helium-cadmium laser, emitting UV light. In the first case fluorescence signals were collected using the standard configuration of the flow cytometer (green fluorescence, representing FITC directly or indirectly labeled antibodies; red fluorescence representing Cy-Chrome tagged anti-pRb T mAb). In the second case, DNA content was analyzed based on DAPI fluorescence (blue emission) excited by UV light, while the anti-pRb P− mAb (FITC) and anti-pRb T (Cy-Chrome) related emission was excited with blue light laser. Additional details of the multicolor measurement of cellular fluorescence and multivariate cell analysis are presented elsewhere. 26, 28, 30 Immunoblotting To reveal specificity of the used antibodies, a standard immunoblotting procedure was used on cellular lysates, as described by us before.
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Controls
Several controls have been done to ascertain specificity of immunocytochemical detection of the studied proteins. Thus, in addition to the generally accepted control of the isotypic irrelevant antibody, MOLT-4 cells, known to have deleted gene coding for p16 INK4A , 31 have been used as control cells for specificity of anti-p16
INK4A mAb. The specificity of mAb reacting with underphosphorylated pRb was tested in several laboratories (reviewed in Ref. 26 ) and in a separate study using alkaline phosphatase to delete the phosphate moiety from pRb and CDK inhibitors, such as staurosporine to prevent its phosphorylation. 26 Parallel Western blots were done as well. All experiments were repeated at least three times, yielding essentially identical results.
Results
In pilot experiments we have found that 170 nm (20 g/ml) was the concentration of onconase at which its cytostatic effect on U937 was apparent and yet cytotoxicity, during the initial 72 h of treatment, relatively low. At that drug concentration cell proliferation was suppressed by approximately 50% and fewer than 10% cells were dead ( Figure 1a ). This concentration of onconase, therefore, was used in most experiments throughout this study.
As is evident from the data shown in Figure 1b in cultures containing onconase proportion of cells in G 0/1 phase was progressively increasing, from 47 to nearly 70% after 72 h, concomitant with a decrease in number of S and G 2 /M cells. A minor increase in percentage of apoptotic cells, from 2 to 6%, also was seen in the onconase-treated cultures. Apoptotic cells were identified on the cellular DNA content frequency histograms as the cells with fractional DNA content ('sub-G 1 ' cell population; see Ref. 32) . Analysis of their morphology by microscopy, as described before 15, 32 revealed typical features of apoptosis (see Discussion).
Immunocytochemical detection of any protein, eg such as cyclin or CKI, when correlated with cellular DNA content measurement (the latter identifying the cell cycle position) reveals, via analysis of the bivariate distributions such as scattergrams or contour maps, the cycle phase specificity of expression of this protein. Such analysis of cyclin D3 expression in the untreated and onconase treated U937 cells is presented in Figure 2 . These scattergrams demonstrate that 
Figure 2
Effect of onconase on expression of cyclin D3 by U937 cells. Cyclin D3 was detected imunocytochemically, and anti-cyclin D3 mAb immunofluorescence in combination with DNA content, was measured by multiparameter flow cytometry (a). The cells were growing either in the absence (Exp, exponential growth) or in the presence of 170 nm onconase for 48 h (Onc). There were 48, 38 and 14% cells in expression of cyclin D3 in exponentially growing untreated cells was unscheduled (Figure 2 ; Onc 0 h). Namely, unlike in normal nontumor cells where this protein is transiently expressed in mid-G 1 cells and is undetectable in S and G 2 /M cells, 23, 29, [33] [34] [35] its expression in U937 cells was continuous during the cycle, including S and G 2 /M phases. The overall level of cyclin D3 was reduced, however, in the cells growing in the presence of onconase. The decrease by about 20% was already observed after 24 h, but it was more pronounced after 48 h when the reduction was over 70% (Figure 2) . However, because the range of reduction appeared to be similar regardless of the cycle phase, the pattern of cyclin D3 expression across the cell cycle still remained unscheduled. Analysis of intensities of the bands on the Western blots (Figure 2b) confirmed the flow cytometric data showing the decrease in expression of cyclin D3 in onconase-treated cells.
In contrast to cyclin D3, the pattern of cyclin E expression in the untreated U937 cells was similar to that seen in the nontumor cells such as proliferating lymphocytes or fibroblasts, 23,25,34 ie its maximal expression was on schedule, timely correlated with the cell entrance to S phase. However, unlike cyclin D3, expression of cyclin E was not significantly changed in the cells growing in the presence of onconase (not shown).
Expression of each of the CKIs, p16
INK4A
, p21 WAF1/CIP1 and p27 KIP1 was markedly elevated in the cells growing in the presence of onconase ( Figures 3, 4 and 5) . The greatest increase was observed for p16 INK4A , whose level rose over six-fold after 72 h incubation with the drug. Over four-fold increase was observed for p27 KIP1 and p21 WAF1/CIP1 . Similarly as in the case of cyclin D3, the increase was not specific to any particular cell cycle phase but was of comparable degree across the whole cell cycle, for each of the studied CKIs.
The status of pRb phosphorylation in U937 cells growing in the absence and presence of onconase was monitored immunocytochemically using two anti-pRb antibodies, one which reacts with this protein regardless of the state of its phosphorylation and thus detects total pRb (anti-pRb T ), and another which binds specifically to underphosphorylated pRb and is not reactive with the phosphorylated form of this protein (anti-pRb P− , Figure 6 ). Several lines of evidence, discussed in greater detail before, 26 indicate specificity of these antibodies to the underphosphorylated vs total pRb, respectively. Briefly, the hybridoma clone G99-549 secreting mouse mAb of IgG1 isotype against pRb P− was derived from a fusion in which underphosphorylated human pRb produced in Sf9 insect cells served as the immunogen. From many obtained hybridoma clones positive for recognizing pRb in Western blots only a single clone identified the underphosphorylated forms of p105
Rb . The epitope recognized by clone G99-549 was mapped to be between amino acids 514-610, which is located within a 'A box' of a large T-antigen binding pocket domain of human pRb. 26, 36 Most likely G99-549 mAb does not recognize an unphosphorylated phosphorylation consensus as such but rather a different structural conformation of pRb P− . Several control experiments were performed to show that the faster migrating forms of pRb recognized by this mAb were indeed lacking phosphorylation. Specifically, (1) when a control mAb (G3-245) that reacts with all forms of pRb (it recognizes an epitope between amino acids 300 and 380 of human pRb; reviewed in Ref. 26 ) was used with 32 P-labeled cells, the ratio of labeled phosphorylated pRb to total pRb precipitated by G3-245 was over 100-fold greater than the ratio obtained with G99-549; (2) when phosphorylated pRb was dephosphorylated by alkaline phosphatase in vitro the Western blot bands with G3-245 and G99-549 mAbs become similar; (3) when all forms of pRb were immunoprecipitated with G3-245 mAb followed by Western blotting with G99-549 mAb, a specific band for faster moving pRb was obtained; and (4) G99-549 mAb identified pRb specifically in pRb expressing Baculovirus-infected insect cells on Western blots, whereas mock-infected insect cells gave no specific signal for this antibody. Taken together, all these results show that G99-549 clone mAb binds selectively to underphosphorylated form of human pRb while anti-pRb T mAb has no such specificity. The specificity of this anti-pRb P− mAb was also confirmed by other authors (eg Ref. 36) .
Incubation of cells with onconase had no effect on total pRb, as detected by antibody which reacts with this protein regardless of its phosphorylation status (anti-pRb T ; data not shown). The effect, however, was apparent in binding the antipRb P− mAb ( Figure 6 ). In a population of exponentially growing cells from the control culture relatively few (2.4%) cells reacted with anti-pRb P− mAb and essentially all these cells had a G 0/1 DNA content; the cells in S, G 2 /M as well as most cells in G 0/1 phase were anti-pRb P− negative. The proportion of cells stainable with anti-pRb P− was increased to 40.5 and 43.3% in cultures treated with onconase for 48 and 72 h, respectively. As an additional control served the cells from the culture which was maintained without re-seeding and medium change until it reached a density over 10 6 cells/ml (Figure 6d ). The cells become arrested in G 0/1 in this culture as well, and similar to the onconase-treated cultures maintained at lower cell density, had also increased proportion of G 0/1 cells reacting with anti-pRb P− .
Discussion
Changes in expression of the cell cycle associated proteins and pRb phosphorylation have been presently investigated using immunocytochemical techniques in combination with multiparameter flow cytometry. This approach offers several advantages and provides complementary information to the standard analysis by Western blotting. The most advantageous is the possibility to detect intercellular variability and correlate expression of the studied proteins with the cell cycle position without a need for cell synchronization in the cycle. Synchronization of tumor-transformed cells, which requires use of the agents suppressing DNA replication, induces significant growth imbalance which leads to experimental bias, especially in analysis of the components of the cell cycle regulatory machinery. 37, 38 Progression of U937 cells through the cell cycle was perturbed in the presence of onconase which manifested in an accumulation of cells in G 0/1 . The cytostatic effect occurred with a delay and significant accumulation of G 0/1 cells was seen only after 24 h of incubation with the drug. The observed increase in proportion of cells in G 0/1 confirmed our earlier findings on other types of cells treated with onconase, 1, 6 and indicated that in the presence of this drug, U937 cells become progressively arrested in G 0/1 . The cytotoxic effect, which becomes more pronounced after prolonged incubation with onconase (over 72 h), and manifests as apoptotic cell death, 15 was not a subject of the present study.
Concomitant with cell arrest in G 0/1 , the onconase-treated cells exhibited a decrease in expression of cyclin D3 and increased levels of all the three CKIs. These changes in cyclin D3 or CKIs expression characterized all onconase-treated cells, regardless of their phase in the cycle. Only the G 0/1 arrested cells, however, developed the ability to bind antipRb P− mAb. These data suggest that during cell growth in the presence of onconase, downregulation of cyclin D3, upregulation of the p16 INK4A and p21 WAF1/CIP1 and induction of p27 KIP1 took place when the cells were still progressing through the cycle. Reactivity of the G 0/1 arrested cells with anti-pRb P− mAb indicates that pRb was underphosphorylated in these cells, ie the cells become arrested prior to, or at the restriction point in G 1 which is controlled by phosphorylation of pRb. Since no significant changes were observed in expression of cyclin E, and since pRb of the cells which progressed through S and G 2 /M were phosphorylated, it is likely that once the cells passed the G 0/1 restriction point their progression through the remainder of the cycle was unaffected in the presence of onconase.
Each of the observed changes in expression of cyclin D3 or CKIs alone may be held accountable for the suppression of pRb phosphorylation leading to cells arrest in G 0/1 . Thus, the D-type cyclins are activators of Cdk4/6, the protein kinases which specifically target pRb for phosphorylation during G 1 . 17, 20, 39, 40 Cyclins of D type are tissue-specific and cyclins D2 and D3 are expressed in hematopoietic cells. 41 
p21
WAF1/CIP1 binds stoichiometrically to multiple Cdks blocking activation of the Cdk/cyclin complexes and suppressing their ability to phosphorylate substrates, notably pRb. [42] [43] [44] This inhibitor can be induced either via activation of the tumor suppressor gene p53, 42, 43 or independently of p53, by two growth suppressing factors, transforming growth factor ␤ (TGF-␤) and interferon regulatory factor 1 (IRF-1). 45, 46 The interaction between interferons and p21 WAF1/CIP also involves signal transducing activators of transcription (STAT) proteins since one of these proteins (STAT1) induces expression of this CKI. 47 It is likely that suppression of cell growth by interferons is mediated via induction of p21.
WAF1/CIP1
Similar to p21 WAF1/CIP1 , p27 KIP1 binds to the Cdk/cyclin complexes and targets multiple Cdks. [48] [49] [50] Also, as p21 WAF1/CIP1 , it mediates TGF-␤ activity via affecting pRb phosphorylation and arresting cells in G 1 and S. It is not surprising, therefore, that p27 KIP1 -deficient mice show similarity to retinoblastoma genedeficient mice, both characterized by hyperplasia of many organs having pituitary dysfunction. 51 Unlike the two first CKIs, the INK family member p16 INK4A specifically binds to Cdk4 (rather than to the Cdk/cyclin complex) and inhibits activity of Cdk4/cyclin D. 52 A vast body of literature indicates that overexpression or ectopic expression of p16 INK4A prevents pRb phosphorylation (eg Refs 53 and 54). Onconase, by downregulating expression of cyclin D3 as well as enhancing expression of each of the three CKIs, has multiple intermediate pathways to prevent pRb phosphorylation in G 1 .
A common feature of tumor cells is the abrogation of cell cycle checkpoints, in particular the G 1 checkpoint, either by aberrant expression of positive regulators (cyclins and Cdks), loss of negative regulators (CKIs) or both (for review, see Ref. 55 ). All components of the cell cycle regulatory machinery whose expression, as shown in the present study, was modulated by onconase, are frequently abnormal or deleted in cancer. Thus, aberrant expression or deletion of the gene coding for p16 INK4A , the so-called multiple tumor suppressor-1 (MTS1), which is located on chromosome 9p21, is a common feature in a variety of tumors, in particular melanomas, acute lymphocytic leukemias, gliomas and mesotheliomas. [56] [57] [58] The gene encoding p27 KIP1 is located on chromosome 12p13 and this chromosome fragment is aberrant in several hematological tumors and myeloproliferative disorders. The gene of p21 WAF1/CIP1 present on chromosome 6p21 appears to be involved in various tumors by virtue of its downstream of p53 functional role. 59, 60 The antitumor potency of onconase, may thus be related to its ability to substitute for loss of a function of each of the above gene products in terms of prevention of pRb phosphorylation.
As mentioned in the Introduction, onconase is a novel drug and its mechanism of action is still an enigma. The ribonuclease activity of onconase appears to be a prerequisite for its cytostatic and cytotoxic properties. 8, 10 This protein is present in amphibian eggs and early embryos where its physiological role is unknown. Since fertilized eggs do divide one may expect that some inhibitor of enzymatic activity of onconase is present within the eggs. It is difficult to visualize the mechanism by which this ribonuclease may selectively affect the cell cycle regulatory molecules as presently observed, namely downregulate expression of cyclin D3, have no effect on cyclin E, and augment expression of all three CKIs. The mechanism proposed in earlier studies, via degradation of tRNA, 8 cannot be selective enough to explain the present findings, especially enhancement of CKIs expression. It was also puzzling to observe that all three CKIs were upregulated by onconase.
It is tempting to speculate that some RNA or ribonuclein complex which has regulatory function may be present in the cell and that this RNA may be a target of onconase. Its degradation may trigger a specific response in terms of modulation of the cell cycle progression, as presently seen. An intriguing possibility is that activity of the double-stranded (ds) RNAdependent protein kinase (PKR), the enzyme which phosphorylates IB and thereby activates the ubiquitous transcription factor NFB (for reviews, see Refs 61, 62) , may be affected by onconase via degradation of the dsRNA regulatory of this kinase. Among a multitude of genes activated by NFB there are genes which regulate cell growth. It is possible, therefore, that dsRNA is one of the onconase targets and its degradation results in inhibition of PKR which may lead to suppression of cell proliferation. In parallel to its cytostatic effect, onconase induces cell apoptosis. 15 The apoptotic pathway can also be linked with onconase via NFB, since interference with activation of this transcription factor is known to prevent expression of the cell survival factors and enhances sensitivity to apoptosis. [61] [62] [63] Results of our recent experiments, utilizing the cells with defective NFB pathway 64 to study effects of onconase, suggest involvement of this pathway in modulation of onconase cytotoxicity (submitted for publication).
